The 17 references in paper Yulia Fedotkina A., Ю. Федоткина А. (2018) “КАК ЛЕЧИТЬ ВТЭО У ОНКОЛОГИЧЕСКИХ ПАЦИЕНТОВ В ОСТРОМ ПЕРИОДЕ? ПРОДЛЕННОЕ ЛЕЧЕНИЕ. РОЛЬ ПРЯМЫХ ОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ. РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ HOKUSAI VTE CANCER // HOW TO TREAT VTEC IN CANCER PATIENTS IN THE ACUTE PERIOD? EXTENDED TREATMENT. THE ROLE OF DIRECT ORAL ANTICOAGULANTS. THE RESULTS OF HOKUSAI VTE CANCER STUDY” / spz:neicon:aterotromboz:y:2018:i:2:p:28-35

1
Levitan n., Dowlati A., Remick s. C., et. al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. medicine (Baltimore). 1999; 78: 285–91.
(check this in PDF content)
2
Farge D., Khorana A.l. et al. International clinical practice guidelines in the treatment and prophylaxis Vte in patients with cancer. Lancet Oncol. 2016; 17: e452–66.
(check this in PDF content)
3
schulman s., Kearon C., Kakkar A. K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. n Engl J med. 2009; 361: 2342–52.
(check this in PDF content)
4
schulman s., Kakkar A. K., Goldhaber s. Z., et al. treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–72.
(check this in PDF content)
5
Bauersachs R., Berkowitz s. D., Brenner B., et al. oral rivaroxaban for symptomatic venous thromboembolism. n. Engl. J. med. 2010; 363: 2499–510.
(check this in PDF content)
6
Buller H. R., Prins M. H., Lensin A. W., et al. oral rivaroxaban for the treatment of symptomatic pulmonary embolism. n. Engl. J. med. 2012; 366:1287–97.
(check this in PDF content)
7
Prins M. H., Lensing A. W., Bauersachs R., et al. oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the eInsteIn-DVt and Pe randomized studies. Thromb. J. 2013; 11: 21.
(check this in PDF content)
8
Agnelli G., Buller H. R., Cohen A., et al. oral apixaban for the treatment of acute venous thromboembolism. n. Engl. J. med. 2013; 369: 799–808.
(check this in PDF content)
9
Agnelli G., Buller H. R., Cohen A., et al. oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J. Thromb. Haemost. 2015; 13: 2187–91.
(check this in PDF content)
10
Buller H. R., Decousus H., Grosso M. A., et al. edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. n. Engl. J. med. 2013; 369: 1406–15.
(check this in PDF content)
11
schulman s., Goldhaber s. Z., Kearon C., Kakkar A. K., schellong s., eriksson H., Hantel s., Feuring M., Kreuzer J. treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb. Haemost. 2015; 114: 150–157.
(check this in PDF content)
12
Raskob G. e., van es n., segers A. et al. edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-Vte randomised, double-blind, doubledummy trial. Lancet Haematol. 2016; 3: e379 – e387.
(check this in PDF content)
13
Vedovati M. C., et al. Direct oral anticoagulants in patients with Vte and cancer: a systematic review and meta-analysis. Chest. 2015; 147: 475–483.
(check this in PDF content)
14
Raskob G. e., van es n., et al edoxaban for the treatment of cancer-associated venous thromboembolism nEJm. 2017 Dec 12.
(check this in PDF content)
15
Young A., et al. Anticoagulation therapy in selected Cancer Patients at Risk of Recurrence of Venous thromboembolism: Results of the select-D Pilot trial. ASH. 2017; Abstract 625.
(check this in PDF content)
16
McBane R. II, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. the ADAM Vte trial. Thromb. Haemost. 2017; 117. https:// doi.org/10.1160/tH17-03–0193.
(check this in PDF content)
17
Khorana A. A. Role of direct oral anticoagulants in treatment of cancer-associated venous thromboembolism: guidance the ssC of the IstH. Journal of Thrombosis and Haemostasis. 2018; 16: 1–4. 105082, Москва, ул. Бакунинская, 71, стр. 10.
(check this in PDF content)